Abstract
We read with great interest the recent report in Clinical Chemistry by Cantürk et al. (1). These authors affirmed that the CYP21A1P1 (cytochrome P450, family 21, subfamily A, polypeptide 1 pseudogene) genotype interferes with quantitative multiplex ligation-dependent probe amplification (MLPA) analysis of the CYP21A2 (cytochrome P450, family 21, subfamily A, polypeptide 2) gene. They also reported that the p.I172N and p.Q318X mutations were absent in 3.6% and 8.5%, respectively, of the CYP21A1P alleles (200 unrelated individuals examined)
Lingua originale | English |
---|---|
pagine (da-a) | 1079-1080 |
Numero di pagine | 2 |
Rivista | Clinical Chemistry |
Volume | 57 |
DOI | |
Stato di pubblicazione | Pubblicato - 2011 |
Keywords
- Hyperplasia